Anticonvulsant action of fluzinamide (AHR-8559) on kindled amygdaloid seizures

Timothy E Albertson, R. M. Joy, L. G. Stark

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The anticonvulsant properties of fluzinamide (AHR-8559) were evaluated in the kindled amygdaloid seizure model in rats. Fluzinamide significantly attenuated afterdischarge durations and the severity of the accompanying convulsive responses in previously kindled rats at doses that did not cause sedation or ataxia. After acute intraperitoneal injections, the maximum anticonvulsant effectiveness against suprathreshold (400 μA) stimulation was seen at 30 min. Fluzinamide (10-80 mg/kg i.p.) was also evaluated in previously kindlet rats using threshold (20-μA increments) seizures. Low doses of fluzinamide significantly elevated seizure threshold and reduced both elicited afterdischarge durations and seizure severity. When administered daily during kindling acquisition, fluzinamide (20 and 40 mg/kg i.p.) significantly increased the number of trials necessary to complete kindling. The duration and the severity of the responses induced by stimulations during the acquisition period were reduced. Previous studies have shown that the anticonvulsant profile for fluzinamide, as determined by traditional electrical and clinical models of epilepsies, most closely resembled phenobarbital and valproic acid, and differed from phenytoin and ethosuximide. The current study is consistent with this profile, with fluzinamide - like phenobarbital and valproic acid - significantly modifying both acquisition of kindling and the fully kindled amygdaloid seizure.

Original languageEnglish (US)
Pages (from-to)511-517
Number of pages7
JournalEpilepsia
Volume25
Issue number4
StatePublished - 1984

Fingerprint

Anticonvulsants
Seizures
Valproic Acid
Phenobarbital
Ethosuximide
fluzinamide
Phenytoin
Ataxia
Intraperitoneal Injections
Epilepsy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Anticonvulsant action of fluzinamide (AHR-8559) on kindled amygdaloid seizures. / Albertson, Timothy E; Joy, R. M.; Stark, L. G.

In: Epilepsia, Vol. 25, No. 4, 1984, p. 511-517.

Research output: Contribution to journalArticle

Albertson, Timothy E ; Joy, R. M. ; Stark, L. G. / Anticonvulsant action of fluzinamide (AHR-8559) on kindled amygdaloid seizures. In: Epilepsia. 1984 ; Vol. 25, No. 4. pp. 511-517.
@article{63a1e127f9e4471fb95eda01e1cd0d04,
title = "Anticonvulsant action of fluzinamide (AHR-8559) on kindled amygdaloid seizures",
abstract = "The anticonvulsant properties of fluzinamide (AHR-8559) were evaluated in the kindled amygdaloid seizure model in rats. Fluzinamide significantly attenuated afterdischarge durations and the severity of the accompanying convulsive responses in previously kindled rats at doses that did not cause sedation or ataxia. After acute intraperitoneal injections, the maximum anticonvulsant effectiveness against suprathreshold (400 μA) stimulation was seen at 30 min. Fluzinamide (10-80 mg/kg i.p.) was also evaluated in previously kindlet rats using threshold (20-μA increments) seizures. Low doses of fluzinamide significantly elevated seizure threshold and reduced both elicited afterdischarge durations and seizure severity. When administered daily during kindling acquisition, fluzinamide (20 and 40 mg/kg i.p.) significantly increased the number of trials necessary to complete kindling. The duration and the severity of the responses induced by stimulations during the acquisition period were reduced. Previous studies have shown that the anticonvulsant profile for fluzinamide, as determined by traditional electrical and clinical models of epilepsies, most closely resembled phenobarbital and valproic acid, and differed from phenytoin and ethosuximide. The current study is consistent with this profile, with fluzinamide - like phenobarbital and valproic acid - significantly modifying both acquisition of kindling and the fully kindled amygdaloid seizure.",
author = "Albertson, {Timothy E} and Joy, {R. M.} and Stark, {L. G.}",
year = "1984",
language = "English (US)",
volume = "25",
pages = "511--517",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Anticonvulsant action of fluzinamide (AHR-8559) on kindled amygdaloid seizures

AU - Albertson, Timothy E

AU - Joy, R. M.

AU - Stark, L. G.

PY - 1984

Y1 - 1984

N2 - The anticonvulsant properties of fluzinamide (AHR-8559) were evaluated in the kindled amygdaloid seizure model in rats. Fluzinamide significantly attenuated afterdischarge durations and the severity of the accompanying convulsive responses in previously kindled rats at doses that did not cause sedation or ataxia. After acute intraperitoneal injections, the maximum anticonvulsant effectiveness against suprathreshold (400 μA) stimulation was seen at 30 min. Fluzinamide (10-80 mg/kg i.p.) was also evaluated in previously kindlet rats using threshold (20-μA increments) seizures. Low doses of fluzinamide significantly elevated seizure threshold and reduced both elicited afterdischarge durations and seizure severity. When administered daily during kindling acquisition, fluzinamide (20 and 40 mg/kg i.p.) significantly increased the number of trials necessary to complete kindling. The duration and the severity of the responses induced by stimulations during the acquisition period were reduced. Previous studies have shown that the anticonvulsant profile for fluzinamide, as determined by traditional electrical and clinical models of epilepsies, most closely resembled phenobarbital and valproic acid, and differed from phenytoin and ethosuximide. The current study is consistent with this profile, with fluzinamide - like phenobarbital and valproic acid - significantly modifying both acquisition of kindling and the fully kindled amygdaloid seizure.

AB - The anticonvulsant properties of fluzinamide (AHR-8559) were evaluated in the kindled amygdaloid seizure model in rats. Fluzinamide significantly attenuated afterdischarge durations and the severity of the accompanying convulsive responses in previously kindled rats at doses that did not cause sedation or ataxia. After acute intraperitoneal injections, the maximum anticonvulsant effectiveness against suprathreshold (400 μA) stimulation was seen at 30 min. Fluzinamide (10-80 mg/kg i.p.) was also evaluated in previously kindlet rats using threshold (20-μA increments) seizures. Low doses of fluzinamide significantly elevated seizure threshold and reduced both elicited afterdischarge durations and seizure severity. When administered daily during kindling acquisition, fluzinamide (20 and 40 mg/kg i.p.) significantly increased the number of trials necessary to complete kindling. The duration and the severity of the responses induced by stimulations during the acquisition period were reduced. Previous studies have shown that the anticonvulsant profile for fluzinamide, as determined by traditional electrical and clinical models of epilepsies, most closely resembled phenobarbital and valproic acid, and differed from phenytoin and ethosuximide. The current study is consistent with this profile, with fluzinamide - like phenobarbital and valproic acid - significantly modifying both acquisition of kindling and the fully kindled amygdaloid seizure.

UR - http://www.scopus.com/inward/record.url?scp=0021184337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021184337&partnerID=8YFLogxK

M3 - Article

C2 - 6745221

AN - SCOPUS:0021184337

VL - 25

SP - 511

EP - 517

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 4

ER -